Treat to target or "treat to clear" in inflammatory bowel diseases: one step further?

Date publication

août 2020

Journal

Expert review of gastroenterology & hepatology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Dal Buono A, Roda G, Argollo M, Zacharopoulou E, Peyrin-Biroulet L, Danese S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32762582

Résumé

Inflammatory bowel diseases (IBD), are chronic and progressive diseases. Long-term complications are demolitive surgery and colon-rectal cancer. A "treat to target" strategy, in which the treatment aims to achieve objective outcomes, has already been introduced in the management of chronic conditions as rheumatic diseases. This approach is emerging as suitable for ulcerative colitis and Crohn's disease. Targets are pre-defined therapeutic goals demonstrated to prevent end-organ dysfunction . An optimization or switch of therapy is considered depending on the target's achievement, with regular monitoring.

Mots clés

histological healing, inflammatory bowel diseases, long-term outcomes, mucosal healing, remission, treat-to-target

Référence

Expert Rev Gastroenterol Hepatol. 2020 Aug 7;: